This lecture explores options for patients with metastatic renal cell carcinoma (RCC) following treatment with VEGF-TKI-targeted agents and ex options for patients with metastatic RCC following treatment with immune checkpoint inhibitors (ICIs), including other ICIs and agents with novel targets.